1.Synthesis of 4-, 6- or 7-substituted phenyliminomethylenecoumarins and their anticancer activities.
Song XU ; Shi-ping XU ; Lan-min LI
Acta Pharmaceutica Sinica 2002;37(2):113-116
AIMA series of substituted phenyliminomethylenecoumarins derivatives was designed in order to find compounds possessing anticancer activities.
METHODSTitle compounds (1a-b, 2a-b and 3a-q) were synthesized and screened by several anticancer models in vitro.
RESULTSTwenty-one new compounds (1a-b, 2a-b and 3a-q) were synthesized and screened. Structures of the new compunds were determined by MS, HNMR and elemental analysis. Twelve compounds (3c, 3d, 3e, 3f, 3g, 3h, 3j, 3k, 3m, 3o, 3p, 3q) showed inhibitory effects on HCT-8, KB and Bel7402 cell lines in vitro.
CONCLUSIONSome compounds had certain anticancer activities and were worth further studying.
Antineoplastic Agents ; chemical synthesis ; chemistry ; pharmacology ; Carcinoma, Hepatocellular ; pathology ; Colonic Neoplasms ; pathology ; Coumarins ; chemical synthesis ; chemistry ; pharmacology ; Humans ; Imines ; chemical synthesis ; chemistry ; pharmacology ; KB Cells ; drug effects ; Liver Neoplasms ; pathology ; Molecular Structure ; Tumor Cells, Cultured ; drug effects
2.LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression.
Ja Eun KIM ; Hong Sook KIM ; Yong Jae SHIN ; Chang Seok LEE ; Cheolhee WON ; Sin Ae LEE ; Jung Weon LEE ; Youngsoo KIM ; Jae Seung KANG ; Sang Kyu YE ; Myung Hee CHUNG
Experimental & Molecular Medicine 2008;40(5):514-522
Tumor migration/invasion is the main cause of tumor progression and STAT3 is needed to enhance tumor migration/invasion by up-regulating MMP-9. Thus, agents that inhibit STAT3 activation may be used as an anticancer drug. We present herein that 6-methyl-2-propylimino-6, 7-dihydro-5H-benzo [1, 3]-oxathiol- 4-one (LYR71) , a derivative of trimeric resveratrol, has an anticancer activity through inhibition of STAT3 activation. We found that LYR71 suppressed STAT3 activation and inhibited the expression and activity of MMP-9 in RANTES-stimulated breast cancer cells. In addition, LYR71 reduced RANTES-induced MMP-9 transcripts by blocking STAT3 recruitment, dissociating p300 and deacetylating histone H3 and H4 on the MMP-9 promoter. Furthermore, LYR71 inhibited tumor migration/invasion in RANTES-treated breast cancer cells and consequently blocked tumor progression in tumor-bearing mice. Taken together, the results of this study suggest that LYR71 can be therapeutically useful due to the inhibition effect of STAT3-mediated MMP-9 expression in breast cancer cells.
Animals
;
Antineoplastic Agents/chemistry/*pharmacology
;
Bicyclo Compounds, Heterocyclic/chemistry/*pharmacology
;
Blotting, Western
;
Breast Neoplasms/genetics/metabolism/pathology
;
Cell Line, Tumor
;
Cell Movement/drug effects
;
Cell Survival/drug effects
;
Chromatin Immunoprecipitation
;
Female
;
Gene Expression/drug effects
;
Humans
;
Imines/chemistry/*pharmacology
;
Immunohistochemistry
;
Mammary Neoplasms, Experimental/pathology/prevention & control
;
Matrix Metalloproteinase 9/genetics/*metabolism
;
Mice
;
Mice, Inbred BALB C
;
Mice, Nude
;
Molecular Structure
;
Phosphorylation/drug effects
;
Reverse Transcriptase Polymerase Chain Reaction
;
STAT3 Transcription Factor/genetics/*metabolism
;
Stilbenes/chemistry
;
Xenograft Model Antitumor Assays/methods